Development and dissolution studies of bisphosphonate (clodronate)-containing hydroxyapatite–polylactic acid biocomposites for slow drug delivery
- Publication Type:
- Journal Article
- Journal of Tissue Engineering and Regenerative Medicine, 2017, 11 (6), pp. 1723 - 1731
- Issue Date:
Files in This Item:
|Macha_et_al-2015-Journal_of_Tissue_Engineering_and_Regenerative_Medicine.pdf||Published Version||648.51 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Copyright © 2015 John Wiley & Sons, Ltd. An increase in clinical demand on the controlled release of bisphosphonates (BPs) due to complications associated with systemic administration, has been the current driving force on the development of BP drug-release systems. Bisphosphonates have the ability to bind to divalent metal ions, such as Ca2+, in bone mineral and prevent bone resorption by influencing the apoptosis of osteoclasts. Localized delivery using biodegradable materials, such as polylactic acid (PLA) and hydroxyapatite (HAp), which are ideal in this approach, have been used in this study to investigate the dissolution of clodronate (non-nitrogen-containing bisphosphonate) in a new release system. The effects of coral structure-derived HAp and the release kinetics of the composites were evaluated. The release kinetics of clodronate from PLA–BP and PLA–HAp–BP systems seemed to follow the power law model described by Korsmeyer–Peppas. Drug release was quantified by 31P-NMR with detection and quantification limits of 9.2 and 30.7 mM, respectively. The results suggest that these biocomposite systems could be tuned to release clodronate for both relatively short and prolonged period of time. In addition to drug delivery, the degradation of HAp supplies both Ca2+ and phosphate ions that can help in bone mineralization. Copyright © 2015 John Wiley & Sons, Ltd.
Please use this identifier to cite or link to this item: